Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Hybrid Metal and Organic Nanoparticles for Targeting, Imaging, and Treating Cancer

Abstract:
Using a set of three biocompatible polymers and a nanoparticle containing gadolinium, a team of investigators at the Colorado School of Mines has created a nanoparticle platform that has the potential to target, image, and treat cancer. Gadolinium ions are used widely in medical imaging because of their ability to dramatically boost magnetic resonance imaging (MRI) signals. However, gadolinium can be toxic, particularly to the kidneys, so researchers have examined numerous ways of creating gadolinium constructs that would shield this element from the body.

Hybrid Metal and Organic Nanoparticles for Targeting, Imaging, and Treating Cancer

Bethesda, MD | Posted on April 27th, 2009

Writing in the journal Biomacromolecules, a team of investigators led by Stephen Boyes, Ph.D., solved this biocompatibility problem while creating a versatile nanoparticle, platform-attaching tumor-targeting molecules, and therapeutic agents. The investigators started by creating gadolinium nanoparticles in which the gadolinium ions were stably constrained with an organic framework. Next, they grew a three-component polymer on a nanoparticle surface using a chemical process known as reversible addition-fragmentation chain transfer (RAFT). The resulting polymer coating proved in tests to be both biocompatible and highly stable. In addition, the coating contained various chemical groups that enabled the researchers to attach the anticancer agent methotrexate and a tumor-targeting peptide known as GRGDS. The researchers note that they could have chosen other targeting and therapeutic agents to attach to the polymer coating.

MRI experiments showed that these nanoparticles generated magnetic signals as strong as those produced by MRI contrast agents now in clinical use, but with one-third less contrast agent. In addition, the investigators showed that one of the polymer components produced a significant fluorescence signal, suggesting that these nanoparticles could provide clinically useful, dual-mode imaging capabilities. Tests with tumor cells grown in culture showed that these nanoparticles were effective at targeting tumor cells, with little uptake by normal cells. Once taken up by tumor cells, the nanoparticles were as effective at killing the cells as was methotrexate.

####

About National Cancer Institute
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.

The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.

Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.

For more information, please click here

Contacts:
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda, MD 20892-2580

Copyright © National Cancer Institute

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

“Polymer-modified gadolinium metal-organic framework nanoparticles used as multifunctional nanomedicines for the targeted imaging and treatment of cancer.”

Related News Press

News and information

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) September 25th, 2018

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

UT engineers develop first method for controlling nanomotors: Breakthrough for nanotechnology as UT engineers develop first method for switching the mechanical motion of nanomotors September 21st, 2018

Imaging

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

Tiny camera lens may help link quantum computers to network September 14th, 2018

Carbon nanodots do an ultrafine job with in vitro lung tissue: New experiments highlight the role of charge and size when it comes to carbon nanodots that mimic the effect of nanoscale pollution particles on the human lung. September 12th, 2018

Govt.-Legislation/Regulation/Funding/Policy

UT engineers develop first method for controlling nanomotors: Breakthrough for nanotechnology as UT engineers develop first method for switching the mechanical motion of nanomotors September 21st, 2018

Researchers develop microbubble scrubber to destroy dangerous biofilms September 19th, 2018

Researchers managed to prevent the disappearing of quantum information September 14th, 2018

New photonic chip promises more robust quantum computers September 14th, 2018

Nanomedicine

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) September 25th, 2018

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

Announcements

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) September 25th, 2018

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project